Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081353 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01081353 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 26 participants.
The verdict
NCT01081353, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
To determine the bioequivalence of new formula of aspirin relative to the established commercial effervescent aspirin when taken orally by healthy adult subjects
Interventions
- DRUG Acetylsalicylic Acid (Aspirin BAY1019036)
- DRUG Alka Seltzer Extra Strength
- DRUG Aspirin Migraine
- DRUG Aspirin Aspro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01081353
The ClinicalTrials.gov registry entry for NCT01081353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Acetylsalicylic Acid (Aspirin BAY1019036) is the first listed.
NCT01081353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01081353 about?
NCT01081353 is a clinical study titled "Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin". To determine the bioequivalence of new formula of aspirin relative to the established commercial effervescent aspirin when taken orally by healthy adult subjects
What is the current status of trial NCT01081353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2010-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT01081353?
The interventions under investigation include: Acetylsalicylic Acid (Aspirin BAY1019036) (DRUG), Alka Seltzer Extra Strength (DRUG), Aspirin Migraine (DRUG), Aspirin Aspro (DRUG).
Who is sponsoring clinical trial NCT01081353?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.